Galapagos NV gave its investors some wobbles during its R&D day in New York Tuesday, revealing that its first-in-class, free fatty acid receptor 2 (FFA2) inhibitor, GLPG974, failed to demonstrate clinical benefit in ulcerative colitis and that recruitment delays will push back top-line data from two phase IIb trials of selective JAK1 inhibitor GLPG634 in rheumatoid arthritis patients.
Shares in Cardio3 Biosciences SA gained almost 6 percent Monday on news that the company raised €25 million (US$33.9 million) from an Asian investor, Medisun International Ltd., which is also committing another €20 million to a joint venture that will take on clinical development and commercialization of its flagship stem cell therapy for ischemic heart failure in the People's Republic of China (PRC), Taiwan and Hong Kong.
Shares in Actelion Ltd. rose 15 percent during trading Monday on news that selexipag, its first-in-class selective oral prostacyclin IP receptor agonist, met the primary endpoint of a phase III outcomes trial in 1,156 patients with pulmonary arterial hypertension (PAH).
The EMA has retreated from its position of allowing researchers only on-screen access to clinical study reports (CSRs) as part of its new policy on clinical data transparency.
The decision by the European Federation of Pharmaceutical Industries Association (EFPIA) to go public this week on Italy's and France's embrace of off-label use of medicines represents a further escalation of an issue it has previously campaigned on behind closed doors.
LYON, France – The European Union's (EU's) research funding programs will play an increasingly prominent role in European research in the coming years, but cash-strapped researchers will have an even tougher time than before in landing the precious funds they need to advance their work.
Affiris AG claims to have achieved the first evidence of disease modification in Alzheimer's, although the result will, for now at least, lead to widespread head-scratching rather than celebration.
Rodin Therapeutics Inc., a company co-founded by Proteros Biostructures GmbH and Atlas Venture, raised $12.9 million in a series A round to take forward two sets of epigenetic modulators that are in development for Alzheimer's disease.
In the coming weeks, Leem, the French pharmaceutical industry lobby group, will present compromise proposals to Social Affairs and Health Minister Marisol Touraine, in an effort to stave off what the group regards as draconian cuts to the country's drugs bill.
The European Medicines Agency (EMA) is coming under increasing pressure over what critics claim is a U-turn in its approach to handling the charged issue of clinical trial data transparency.
